Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Carly Swint

Physician Assistant Centennial, CO Physician Assistant

NPI 1407374408 CMS profile 11219720

6801 S Yosemite St, Centennial, CO 80112

Open in the dashboard

General payments

$7,852

220 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carly Swint of Centennial, CO is reported in the CMS Open Payments database as having received $7,852 across 220 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,370 61
2024 General $2,327 45
2023 General $854 27
2022 General $611 27
2021 General $2,690 60

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carly Swint
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Carly Swint were reported at $1,370. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Carly Swint Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,690 $132 $37–$438 $132
2022 $611 $155 $48–$522 $149
2023 $854 $167 $52–$557 $160
2024 $2,327 $178 $55–$600 $164
2025 $1,370 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $1,874 32 payments
  2. CSL Behring $1,659 45 payments
  3. Octapharma USA, Inc. $876 7 payments
  4. Grifols USA, LLC $525 17 payments
  5. Cycle Pharmaceuticals Inc $414 11 payments
  6. Pharming Healthcare, Inc. $292 15 payments
  7. AstraZeneca Pharmaceuticals LP $283 8 payments
  8. ADMA BioManufacturing LLC $235 3 payments
  9. BioCryst US Sales Co., LLC $216 11 payments
  10. Genzyme Corporation $213 9 payments
  11. Other $1,265 62 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,695 203 payments
  2. Consulting Fee $2,176 7 payments
  3. Honoraria $750 1 payment
  4. Education $230 9 payments
Products named General payments · program years 2021–2025
  1. Haegarda $812 30 payments
  2. CUTAQUIG $809 4 payments
  3. TAKHZYRO $672 10 payments
  4. RUCONEST $280 14 payments
  5. HYQVIA $278 12 payments
  6. Hizentra $265 10 payments
  7. Xembify $245 6 payments
  8. Orladeyo $216 11 payments
  9. Sajazir $214 9 payments
  10. FIRDAPSE $174 9 payments
  11. Other $2,418 107 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

316

Median for Physician Assistant: 241

Drug cost

$5,965,212

Median for Physician Assistant: $4,110

Branded share of claims

74.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ruconest C1 Esterase Inhibitor, Recomb Brand 30 $3,258,430
Takhzyro Lanadelumab-Flyo Brand 25 $1,313,412
Haegarda C1 Esterase Inhibitor Brand 39 $836,749
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 14 $233,531
Dupixent Syringe Dupilumab Brand 28 $103,947
Cutaquig Immun Glob G(Igg)-Hipp/Maltose Brand 21 $80,234
Dupixent Pen Dupilumab Brand 12 $68,525
Sajazir Icatibant Acetate Brand 20 $65,661
Cromolyn Sodium Generic 23 $2,979
Valacyclovir Valacyclovir Hcl Brand 31 $847

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$1,224,328

Of which drugs: $1,195,244

Medicare patients

154

Average age 65

Services billed

24,130

114 women, 40 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 49%
Arthritis 49%
Depression 31%
Osteoporosis 23%
Ischemic heart disease 20%
COPD 20%
Diabetes 19%
Chronic kidney disease 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg J1568 Office 27 5,690 $208,964

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Xembify
  • Grifols USA, LLC $172
$172 — —
Haegarda
  • CSL Behring $162
$162 39 —
RUCONEST
  • Pharming Healthcare, Inc. $117
$117 30 —
FASENRA
  • AstraZeneca Pharmaceuticals LP $105
$105 — —
HYQVIA
  • Takeda Pharmaceuticals U.S.A., Inc. $74
$74 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

220 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record